DealsApr 30, 2026, 01:14 PM
OSRH signs $815M global license for VXM01 with BCME; shares pledged
AI Summary
OSR Holdings, Inc. and its subsidiary Vaximm AG entered into a Global Exclusive License Agreement with BCM Europe AG, OSRH's largest shareholder, for the exclusive worldwide license to develop and commercialize VXM01, an oral DNA-based cancer immunotherapy platform. The agreement includes up to $815 million in milestone payments to OSRH. Additionally, BCME and its affiliates pledged 9,974,728 shares of OSRH common stock as collateral for these milestone obligations, effective February 15, 2028. OSRH also gains an equity put option for up to $15 million of its common stock and will acquire VXM01 IP for $30 million.
Key Highlights
- OSRH signed a Global Exclusive License Agreement for VXM01 with BCM Europe AG.
- The agreement includes up to $815,000,000 in aggregate milestone payments to OSRH.
- BCME and affiliates pledged 9,974,728 OSRH shares as collateral for milestone payments.
- The share pledge becomes effective February 15, 2028, after lock-up restrictions expire.
- OSRH has an equity put option to sell up to $15,000,000 of common stock to BCME at $10.00/share.
- OSRH will acquire VXM01 intellectual property from its subsidiary Vaximm for $30,000,000.
- BCME is responsible for VXM01 funding, development, regulatory, and commercialization.
- The related-party transaction was approved by the Board following an independent fairness opinion.